Dr. Scholey’s appointment is an important milestone in expanding the network’s leadership capacity and promoting network sustainability and succession planning. In this role, he will work alongside the Can-SOLVE CKD operations team and the network’s various committees to support the realization of our shared vision for patient-oriented kidney research.
Dr. Scholey is an internationally respected physician and scientist who brings to this role a diverse clinical and research skillset that complements the network’s existing leadership. His full biography is attached below, but special note must be made of his ongoing commitment to Can-SOLVE CKD since the network’s inception. Currently he serves as co-lead of AdDIT, focused on the identification of kidney risk in youth with type 1 diabetes. His leadership has also been evident in his efforts to organize a regional funders’ forum in Toronto hosted April 9 by the University Health Network. The success of this event, which brings funders and other partners together with Can-SOLVE CKD researchers and patients, is a credit to Dr. Scholey’s vision and dedication.
Dr. James Scholey biography
Dr. James Scholey is a Professor of Medicine and Physiology and a Physician Scientist in the Department of Medicine at the University of Toronto. He is also a Senior Scientist in the Toronto General Research Institute and a staff physician in the Division of Nephrology in the Department of Medicine at the University Health network and Mount Sinai Hospital.
Dr. Scholey’s research focuses on mechanism(s) responsible for the progression of chronic kidney disease with a special interest in diabetic nephropathy and the renin angiotensin system. His laboratory employs cell-based and murine models of kidney injury. He also has a longstanding interest in the physiology of human diabetic kidney hyperfiltration and the impact of proteinuria on the progression of glomerulonephritis.
Dr. Scholey’s research program in Can-SOLVE CKD is focused on the identification of kidney risk in youth with diabetes mellitus. These studies are a collaborative effort with researchers at the Hospital for Sick Children in Toronto and researchers at the Children’s Hospital Research Institute in Winnipeg.